Johnson & Johnson to Buy Firefly Bio for $1 Billion to Add Degrader Antibody Conjugate Technology for Oncology
The deal gives J&J a proprietary Firelink platform designed to deliver targeted protein degraders, with an emphasis on KRAS-driven solid tumors.